Humacyte, Inc. — Director's Dealing 2022

Sep 1, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Humacyte, Inc. (HUMA)
CIK: 0001818382
Period of Report: 2022-09-01

Reporting Person: Binder Gordon M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-09-01	Common Stock	P	48159	$4	Acquired	48159	Direct

Footnotes

F1: The shares were purchased in multiple transactions at per share prices ranging from $3.53 to $4.20. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.